CLCS.US Cell Source Inc

Healthcare Biotechnology USA Stocks
0.4400 USD
Close of Nov 12, 2026
0.3250 1.00
Market cap
USD 29.9M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is CLCS.US undervalued?

Graham number

The Graham number of Cell Source Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cell Source Inc fundamental analysis

No fundamental analysis for Cell Source Inc yet.

Cell Source Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cell Source Inc

Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company's Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell tra…

Full company profile